Latest news
Glaukos (GKOS) Is Up 12.9% After Raising 2026 Sales Guidance and Advancing PRESERFLO Trial - webull.comwebull.com · Wed, 05 Aug 2026 01:48:48 GMTGlaukos completes enrollment in PRESERFLO MicroShunt pivotal study - Glance by Eyes On EyecareGlance by Eyes On Eyecare · Tue, 04 Aug 2026 19:44:43 GMTWhy Glaukos (GKOS) Is Up 10.8% After Raising 2026 Sales Guidance And Advancing PRESERFLO Study - Yahoo FinanceYahoo Finance · Fri, 31 Jul 2026 07:08:54 GMTPatient enrolment concludes in Glaukos’ Preserflo MicroShunt trial - Medical Device NetworkMedical Device Network · Tue, 28 Jul 2026 07:00:00 GMTGlaukos Announces Completion of Patient Enrollment in 510(k) Pivotal Study for PRESERFLO™ MicroShunt - BioSpaceBioSpace · Tue, 28 Jul 2026 03:34:04 GMTHow PRESERFLO Trial Enrollment Completion Could Shape Glaukos’ (GKOS) Long-Term Glaucoma Pipeline Strategy - simplywall.stsimplywall.st · Mon, 27 Jul 2026 19:31:20 GMTGlaukos Completes Enrollment in US Pivotal Study of Preserflo MicroShunt for POAG - Eyewire+Eyewire+ · Mon, 27 Jul 2026 12:59:27 GMTGlaukos completes enrollment in pivotal trial of PRESERFLO MicroShunt for treatment-resistant glaucoma - Ophthalmology Times EuropeOphthalmology Times Europe · Mon, 27 Jul 2026 07:00:00 GMT